There is no proven cure for autism spectrum disorder (ASD), and an experimental drug being studied to address some symptoms of the condition has not been demonstrated in large-scale clinical ...

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General ...

PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions PaxMedica, Inc. Tue, Jan 14, 2025, 8:00 AM 3 min read ...

CDC estimates that one in 68 children in the U.S. are on the autism spectrum. Right now, there are no FDA approved treatments for the disorder or its symptoms, which can include difficulty with ...

TARRYTOWN, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General ...

PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions Jan. 14, 2025 8:00 AM ET PaxMedica, Inc. (PXMD) ...

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General ...

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General ...

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General ...